Oncotarget

Research Perspectives:

Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche

Ding-Wen Chen _, Eric K. Wafula and Peter Kurre

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2024; 15:609-613. https://doi.org/10.18632/oncotarget.28642

Metrics: PDF 554 views  |   Full Text 1171 views  |   ?  


Abstract

Ding-Wen Chen1, Eric K. Wafula2 and Peter Kurre1,3

1 Department of Pediatrics, Comprehensive Bone Marrow Failure Center, Division of Hematology, Children’s Hospital of Philadelphia, PA 19104, USA

2 Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, PA 19104, USA

3 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Correspondence to:

Ding-Wen Chen, email: [email protected]
Peter Kurre, email: [email protected]

Keywords: hematopoietic stem and progenitor cells; acute myeloid leukemia; inflammation; innate immune reprogramming; trained immunity

Received: July 19, 2024     Accepted: August 04, 2024     Published: September 04, 2024

Copyright: © 2024 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Lifelong hematopoiesis is sustained by crosstalk between hematopoietic stem and progenitor cells (HSPCs) and specialized bone marrow niches. Acute myeloid leukemia (AML) upends that balance, as leukemic blasts secrete factors that remodel the bone marrow into a self-reinforcing leukemic niche. The inflammatory secretome behind this compartmental adaptation accounts for a progressive decline in hematopoietic function that leads to diagnosis and persists through early treatment. Not surprisingly, the mediators of an acute inflammatory injury and HSPC suppression have attracted much attention in an effort to alleviate morbidity and improve outcomes. HSPCs typically recover during disease remission and re-expand in the bone marrow (BM), but little is known about potentially lasting consequences for stem cells and progenitors. We recently showed that AML-experienced HSPCs actively participate in the inflammatory process during leukemic progression. HSPCs are constituent components of the innate immune system, and elegant studies of infection and experimental inflammation over the past decade have described the generation of an adoptively transferable, innate immune memory. Building on this paradigm, we discuss the potential translational relevance of a durable legacy in AML-experienced HSPC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28642